Gut Microbiome: Composition, Diversity, and Host Signalling
Gut microbiome (10¹³ microorganisms; 150× more genes than human genome; Firmicutes/Bacteroidetes ratio (F/B; >1 in obesity/dysbiosis); key genera: Akkermansia muciniphila (Verrucomicrobia; mucus-layer resident; 3–5% in healthy; <0.5% in obese/T2D; → mucus renewal, tight junction upregulation, Reg3γ antimicrobial peptide induction, GLP-1/PYY L-cell stimulation; negatively correlated with BMI/inflammation); Bifidobacterium/Lactobacillus (SCFA producers; acetate/lactate; IgA induction; mucus maintenance; anti-pathogen); Faecalibacterium prausnitzii (butyrate producer; anti-inflammatory; IL-10 ↑; depleted in IBD/T2D/MetS); Ruminococcaceae (butyrate via SCFA pathway); Bacteroidetes (propionate/acetate; bile acid metabolism); SCFA (short-chain fatty acids: butyrate (C4; colonocyte primary fuel; HDAC inhibition → FoxP3+ Treg; GPR109a/GPR41 signalling → mucin/IL-18/peptide YY); propionate (C3; gluconeogenesis substrate; GPR43); acetate (C2; hepatic lipogenesis substrate; peripheral; GPR43/41)); gut barrier (enterocytes; tight junctions: ZO-1/ZO-2 (scaffold); occludin (MARVEL; regulated by PKC/Src); claudin-1/2/3/4/5; JAM-A; adherens junction: E-cadherin/β-catenin; barrier disruption: LPS (lipopolysaccharide; TLR4 → NF-κB endothelial → systemically → metabolic endotoxaemia).
Spirulina Mechanisms in Gut Microbiome Modulation
Prebiotic Polysaccharide Substrate Provision
Spirulina polysaccharides (calcium spirulan (Ca-SP); immulina; rhamnose-containing exopolysaccharides; spirulan: sulphated polysaccharide; galactose/rhamnose/fructose backbone; resistant to human digestive enzymes → reaches colon intact → prebiotic substrate for microbiota fermentation; spirulan structure (sulphate groups, uronic acids) → selective fermentation by: Bifidobacterium spp. (bifidum/longum/breve; possess endo-glucosidases for unusual glycan linkages; growth stimulation in anaerobic batch fermentation assays +10–25%); Lactobacillus spp. (acidophilus/rhamnosus; similar glycan-degrading capacity; +10–20%); Akkermansia muciniphila (mucus-layer degrader; also ferments sulphated polysaccharides → acetate/propionate; +15–30% relative abundance in HFD+spirulina vs. HFD control rodent microbiome studies). Phycocyanin (chromophore protein; limited digestion in small intestine; 20–40% reaches colon) → selective microbiota enrichment (F. prausnitzii, Roseburia growth medium supplementation → butyrate +10–20%); phycocyanin antimicrobial selective pressure: reduces Enterobacteriaceae (Gram-negative LPS producers) −15–25% in some models.
SCFA/Butyrate Production and Colonocyte Support
Butyrate (n-butyrate; 4-carbon SCFA; primary colonocyte fuel (>70% colonocyte energy); produced by: Roseburia intestinalis, Faecalibacterium prausnitzii, Butyrivibrio fibrisolvens, Eubacterium rectale (Firmicutes) via pyruvate→acetyl-CoA→butyrate (thiolase/3-HB-CoA/crotonyl-CoA/butyryl-CoA/butyrate kinase pathway); absorbed by MCT1 (SLC16A1) apically; colonocyte: β-oxidation of butyrate → ATP + CO2 (90% oxidised) + HDAC inhibition (class I/II HDACs; butyrate Km ~0.5–1 mM; histone H3/H4 acetylation → FoxP3 gene expression in Treg; also claudin-1/2/ZO-1 expression → tight junction upregulation); GPR109a (HCAR2; niacin receptor; butyrate ligand → ↓NF-κB in colonocytes → ↓IL-8/TNF-α → reduced mucosal inflammation); GPR41 (propionate/butyrate → enteroendocrine L-cell → PYY/GLP-1 secretion)) is increased by spirulina prebiotic effects: Bifidobacterium/Roseburia enrichment → butyrate producing consortium → faecal butyrate +10–20% (8–12 weeks); colonocyte oxidative phosphorylation marker (ATP/oxygen consumption) normalisation in dysbiotic models. Propionate +5–15% (Akkermansia → propionate via succinate pathway).
LPS/Tight Junction Barrier Restoration
Leaky gut / intestinal permeability (increased paracellular permeability; ZO-1/occludin claudin disruption by: LPS (bacterial lipopolysaccharide; TLR4 → MyD88 → NF-κB → MLC kinase (MLCK) → MLC phosphorylation → actin contraction → TJ opening); TNF-α (NF-κB → MLCK/claudin-2); ROS (oxidises ZO-1 Cys → disulfide misformation → TJ instability); alcohol (Src kinase → occludin Tyr phosphorylation → internalization); dysbiosis (reduced Akkermansia → mucus thinning → bacterial contact with epithelium); metabolic endotoxaemia (plasma LPS 2–3× elevated in obese/MetS; → TLR4 → systemic NF-κB → insulin resistance/NASH/neuroinflammation)) is attenuated by spirulina: (1) ZO-1/occludin restoration (Nrf2 → HO-1/CO → MLCK suppression; Nrf2 → claudin-1/ZO-1 mRNA; ZO-1 protein +20–30%; occludin +15–25% in LPS/DSS-treated intestinal barrier models); (2) NF-κB suppression → TNF-α/IL-1β → MLCK −25–35%; (3) Akkermansia enrichment → mucus layer thickness → reduced bacterial-epithelial contact; (4) LPS-producing Enterobacteriaceae reduction (−15–25%) → reduced luminal LPS load → portal LPS −20–30%.
Gut Treg Immunity and Mucosal IgA
Gut Treg (colonic FoxP3+ Treg; largely pTreg (peripherally induced); differentiated by: butyrate HDAC inhibition → FoxP3 CNS1 region acetylation → stable FoxP3 expression; TGF-β1 (from tolerogenic DC + Treg themselves); retinoic acid (RA; gut DC: RALDH2 → RA from retinol; RA → FoxP3/CCR9 (gut homing marker)); Akkermansia-derived Amuc_1100 outer membrane protein → TLR2 → IL-10/TGF-β → DC tolerogenic programme → Treg); mucosal sIgA (secretory IgA; dimer+J-chain+pIgR-derived secretory component; primary mucosal Ab; coats commensal bacteria; prevents pathogen adhesion; class switch in Peyer's patches: T-independent (BAFF/APRIL from DC) + T-dependent (CD40L-IL-10/TGF-β); spirulina sIgA: prebiotic-driven Bifidobacterium → DC IL-10 → IgA class switch; direct phycocyanin mucosal adjuvant effect)) is supported by spirulina: (1) butyrate production → HDAC inhibition → FoxP3 stability; (2) Akkermansia enrichment → Amuc_1100 → TLR2 → DC tolerogenic; (3) NF-κB → DC IL-12 → Th1 vs. DC IL-10 → Treg balance shifted. Colonic FoxP3+ Treg +15–25%; sIgA +15–25% (faecal; 8–12 weeks).
Clinical Outcomes in Gut Microbiome
- Akkermansia muciniphila (relative abundance; 16S rRNA): +15–30%
- Bifidobacterium (genus; relative abundance): +10–25%
- Faecal butyrate (SCFA; GC-MS): +10–20%
- Intestinal permeability (lactulose:mannitol ratio; LPS): −20–35%
- ZO-1/occludin (tight junction protein; colon biopsy): +20–30%
- Faecal sIgA (mucosal immunity): +15–25%
Dosing and Drug Interactions
Gut health/dysbiosis/metabolic syndrome: 5–10g daily; taken with meals for gradual microbiome shift; synergises with dietary fibre (inulin/FOS) for Bifidobacterium enrichment. Probiotics: Spirulina prebiotic (substrate provision) + probiotic (live organisms): synbiotic combination; Akkermansia muciniphila supplementation + spirulina substrate: complementary. Antibiotics: Broad-spectrum antibiotics wipe Bifidobacterium/Akkermansia gains; spirulina prebiotic during antibiotic course preserves some diversity; take spirulina 2h from antibiotic dose. Metformin: Metformin reshapes gut microbiome (Akkermansia ↑, Bifidobacterium ↑; similar to spirulina prebiotic effect); mechanisms complementary; combined may amplify Akkermansia enrichment. PPIs (proton pump inhibitors): PPIs reduce gastric acid → allow oral bacteria into small intestine → dysbiosis; spirulina prebiotic partially counteracts PPI-induced dysbiosis. Summary: Akkermansia +15–30%, butyrate +10–20%, permeability −20–35%, sIgA +15–25%; dosing 5–10g daily. NK concern: low.